학술논문
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
Document Type
Article
Author
Reich, D.S.; Arnold, D.L.; Vermersch, P.; Bar-Or, A.; Fox, R.J.; Matta, A.; Turner, T.; Wallström, E.; Zhang, X.; Mareš, M.; Khabirov, F.A.; Traboulsee, A.; Grand'Maison, F.; Jacques, F.; Tyblova, M.; Meluzinova, E.; Ampapa, R.; Valis, M.; Hradilke, P.; Stourac, P.; Gross-Paju, K.; Laplaud, D.; Mathey, G.; Uitdehaag, B.; Evdoshenkoo, E.; Popova, E.; Zakharova, M.; Totolyan, N.; Litvinenko, I.; Khabirov, F.; Sivertseva, S.; Hancinova, V.; Kantorova, E.; Gines, M.L.M.; Montalban, X.; Maduano, S.E.; Meca-Lallana, J.; Ramió-Torrentà, L.; Nehrych, T.; Pashkovskyy, V.; Moskovko, S.; Kalbus, O.; Khavunka, M.; Pryshchepa, V.; Goloborodko, A.; Wynn, D.; Honeycutt, W.; Wray, S.; Steingo, B.; LaGanke, C.; Huang, D.; Hemphill, J.M.; Goldstick, L.; Robertson, D.
Source
In: The Lancet Neurology . (The Lancet Neurology, September 2021, 20(9):729-738)
Subject
Language
English
ISSN
14744465
14744422
14744422